List view / Grid view
Hal V. Barron (born 1962) is an American clinician-scientist and drug developer currently serving as president of research and development at Calico. He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.
Barron joined Genentech in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs. In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.
Barron’s current academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics, and Associate Clinical Professor of Medicine/Cardiology. He has been issued several patents for his work in thrombosis and angiogenesis, and has published more than 90 papers in peer-reviewed scientific journals. He was a member of the board of directors at Alexza Pharmaceuticals.
“This positive opinion from the CHMP is a step toward…
20 December 2013 | By Roche
“This positive opinion from the CHMP is a step toward providing physicians and patients the flexibility to choose whether intravenous or subcutaneous RoActemra treatment..."
Kadcyla is indicated as a single agent for the treatment…
20 November 2013 | By Roche
Kadcyla is indicated as a single agent for the treatment of adults with HER2-positive, unresectable locally advanced or metastatic breast cancer...
Use of new Herceptin formulation reduced the time needed for…
30 September 2013 | By Roche
Use of new Herceptin formulation reduced the time needed for pharmacists and doctors to treat patients...
Kadcyla nearly doubled the time that patients lived without their…
28 September 2013 | By Roche
Kadcyla nearly doubled the time that patients lived without their disease worsening compared with treatment of physician’s choice...
Roche announced that a new injectable (subcutaneous) formulation of Herceptin…
2 September 2013 | By Roche
Roche announced that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission...
Results from the phase III CLL11 study...
24 July 2013 | By Roche
Results from the phase III CLL11 study...
The European Commission has granted conditional approval to Erivedge...
15 July 2013 | By Roche
The European Commission has granted conditional approval to Erivedge...
"The safety of patients is our first priority..."
10 July 2013 | By Roche
"The safety of patients is our first priority..."
FDA decision on the GA101 BLA is expected by the…
3 July 2013 | By Roche
FDA decision on the GA101 BLA is expected by the end of 2013...
The U.S. FDA has accepted the company’s sBLA for the…
2 July 2013 | By Roche
The U.S. FDA has accepted the company’s sBLA for the use of a Perjeta®...
"Over the last 14 years, Herceptin has revolutionised the treatment…
28 June 2013 | By Roche
"Over the last 14 years, Herceptin has revolutionised the treatment of HER2-positive breast cancer..."
First approval of Avastin for the treatment of newly diagnosed…
17 June 2013 | By Roche
First approval of Avastin for the treatment of newly diagnosed glioblastoma...
Roche announced data from two phase III studies...
13 June 2013 | By Roche
Roche announced data from two phase III studies...
“This approval comes earlier than expected, just one month following…
10 June 2013 | By Roche
“This approval comes earlier than expected, just one month following the positive CHMP opinion...”
Results of study GOG240...
2 June 2013 | By Roche
Results of study GOG240...
